Filing Flows › Angiodynamics (ANGO) › Q3 FY25
Angiodynamics (ANGO) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Apr 2, 2025
Angiodynamics (ANGO) reported revenue of $72.0M for the third quarter fiscal 2025 (Q3 FY25), -4% from a year earlier and -1% from the quarter before. Operating margin was -13.9%, net loss $4.4M (6.1% of revenue).
Angiodynamics, Q3 FY25: revenue $72.0M (-4% year over year), operating margin -13.9%, net loss $4.4M, operating cash flow −$13.2M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $72.0M | -1% | -4% |
| Operating profit | −$10.0M | — | — |
| Net earnings | −$4.4M | — | — |
| Operating cash flow | −$13.2M | — | — |
What changed
Revenue was $72.0M in Q3 FY25, down 4% year over year and down 1% from the previous quarter. Med Device was the largest line at 56% of revenue. Med Device lost $8.7M year over year (down 18%), 273% of the total change.
Gross margin was 54.0%, up 6.3 points from a year earlier. Operating costs exceeded revenue by $10.0M, an operating margin of -13.9%. Operating expenses fell 79% while revenue fell 4%. The quarter ended with a net loss of $4.4M, narrower than the previous quarter's $10.7M loss. Non-operating items added $5.6M, -126% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$13.2M. Non-cash charges added back $6.3M of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $17.5M. Capital expenditures of $1.8M exceeded it, leaving free cash flow of −$15.0M.
Questions
What was Angiodynamics' revenue in the third quarter fiscal 2025?
Angiodynamics (ANGO) reported revenue of $72.0M for the third quarter fiscal 2025 (Q3 FY25), -4% from a year earlier and -1% from the quarter before.
Was Angiodynamics profitable in the third quarter fiscal 2025?
Operating loss was $10.0M (-13.9% of revenue) and net loss $4.4M.
Source: Angiodynamics 10-Q on SEC EDGAR.